Using joint research and AI to identify biomarkers that can improve clinical trial success rates and shorten development timelines
First written in FY2024. 2 of 3 entries say "Advanced", first in FY2025. Latest entry: 2026-06-12.
No other company in this theme has enough history to compare yet.
- 2026-06-12AdvancedOther Disclosures
「This study suggests that CDK10 may be a sensitivity biomarker for CTX-439, and these findings are expected to provide foundational knowledge for patient stratification and treatment strategies in future clinical research.」
Publication of the joint research with Kyoto University identified a potential sensitivity biomarker for CTX-439 and demonstrated its validation in cell and animal models. - FY2025AdvancedAnnual report
「National Cancer Center Japan — subcontracted research and development agreement — 1 April 2025 — Development of a system to accelerate drug discovery research for new anticancer drugs using AI — CLK — 31 March 2026」
In addition to the previous AI feasibility study with Kyoto University and Fujitsu, development of an AI-based system to accelerate drug discovery research with the National Cancer Center was formalized under a contract. - FY2024First statedAnnual report
「We have newly launched a feasibility study with Kyoto University and Fujitsu Limited to identify biomarkers that can improve the probability of success and shorten the duration of clinical trials in new cancer drug development, using Fujitsu's AI-based causal discovery technology, which provides clues to new discoveries from data.」
Biomarker research for patient stratification and clinical trial efficiency is under way, including an AI-based feasibility study with Kyoto University and Fujitsu.